FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc.
(Nasdaq: ARDX), a biopharmaceutical company focused on developing
first-in-class medicines to improve treatment for people with
kidney and cardiovascular diseases, today announced that it will
hold a virtual Analyst Day on Thursday,
November 12, 2020, from 9:30 a.m. to
12:00 p.m. ET. This year's event will focus on the company's
launch and commercialization plans in anticipation of the potential
approval of tenapanor for the control of serum phosphorus in adult
patients with chronic kidney disease (CKD) on dialysis.
Additionally, the company will review its pipeline therapeutic for
hyperkalemia.
The management team will be joined by:
- German Hernandez, M.D., FASN,
FACP, associate nephrologist at El Paso Kidney Specialists and
clinical associate professor of medicine at Texas Tech University Health Sciences Center, will
review tenapanor's unique profile.
- Jennifer Robinson, president of
Spherix Global Insights, will present data on the challenges of
treating hyperphosphatemia in patients with CKD on dialysis.
- Douglas Paul, PharmD, Ph.D.,
vice president and partner at MME, will discuss value perceptions
across payers, patients and healthcare professionals.
A live webcast of the event will be available on the Ardelyx
website via the Events and Presentations page under the investor
relations section at
https://ir.ardelyx.com/events-and-presentations.
About Ardelyx, Inc.
Ardelyx is focused on developing
innovative first-in-class medicines to enhance the lives of
patients with kidney and cardiovascular diseases. Ardelyx is
advancing tenapanor, a novel product candidate to control serum
phosphorus in adult patients with CKD on dialysis, for which the
company's NDA is currently under review by the FDA, with a PDUFA
goal date of April 29, 2021. Ardelyx
is also advancing RDX013, a potassium secretagogue program, for the
potential treatment of high potassium, or hyperkalemia, a problem
among certain patients with kidney and/or heart disease. In
addition, Ardelyx received FDA approval of IBSRELA®
(tenapanor) on September 12, 2019.
Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and
commercialization of tenapanor in the respective territories.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ardelyx-to-webcast-virtual-analyst-day-301167749.html
SOURCE Ardelyx